C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.53−0.12 (-4.53%)
Close on Nov 17, 2026Market cap $311.25MP/E –Yield –
C4 Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
C4 Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$111.77M. For fiscal 2025 it was -$115.22M. The highest annual figure on record is -$35.45M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$115.22M | – |
| FY2024 | Dec 31, 2024 | -$119.61M | – |
| FY2023 | Dec 31, 2023 | -$139.03M | – |
| FY2022 | Dec 31, 2022 | -$129.53M | – |
| FY2021 | Dec 31, 2021 | -$82.13M | – |
| FY2020 | Dec 31, 2020 | -$60.45M | – |
| FY2019 | Dec 31, 2019 | -$35.45M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.41M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.24M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.43M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$36.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$38.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.38M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.51M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.35M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.00M | – |
See a number that looks wrong?